RAYMEI

Name

RAYMEI

Legal name

株式会社レイメイ

Website

https://raymei.co.jp

Company type

Private

Founded year

2016

Operating status

Operating

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAGAK

Ophthalmic Regeneration (cornea/retina)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAAABAE

Stem Cell Therapies (MSC/iPSC/HSC-derived)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAIACAK

Ophthalmology Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIAAAO

Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Regenerative medicine
• IPS cell therapy
• Corneal transplants
• Cell sheet therapy
• Ophthalmology treatments

Headquarters

HQ city

Osaka

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Regenerative Medicine Products: RAYMEI is developing and preparing to commercialize iPS cell-derived regenerative medicine products for ophthalmological conditions, specifically corneal epithelial cell sheets and corneal endothelial cells. The company is currently in clinical trial preparation phase and has not yet generated revenue from product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

RAYMEI develops and prepares to commercialize allogeneic iPS cell-derived regenerative medicine products for ophthalmological conditions. The company's primary pipeline consists of corneal epithelial cell sheets for transplantation in patients with limbal stem cell deficiency, and corneal endothelial cells for anterior chamber injection therapy targeting severe bullous keratopathy, both produced via the proprietary SEAM (Self-formed Ectodermal Autonomous Multi-zone) method developed at Osaka University.

Product overview

RAYMEI is a regenerative medicine company developing iPS cell-derived cell therapy products for ophthalmological applications. The company commercializes two primary products: allogeneic iPS cell-derived corneal epithelial cell sheets for limbal stem cell deficiency and allogeneic iPS cell-derived corneal endothelial cells for bullous keratopathy. Both products are based on the SEAM method technology that enables simultaneous two-dimensional induction of eye-related cells including cornea and retina from iPS cells.

Differentiator

Problem solved

Functional benefit

Products and services

• Allogeneic iPS Cell-Derived Corneal Epithelial Cell Sheets (他家iPS細胞由来角膜上皮細胞シート) Regenerative medicine product consisting of cultured corneal epithelial cell sheets derived from allogeneic HLA homozygous iPS cells, developed for transplantation into patients with limbal stem cell deficiency, including Stevens-Johnson Syndrome, ocular pemphigoid, heat/chemical injury, and aniridia. The product is administered via corneal epithelial cell sheet transplantation in hospital/ophthalmology clinic settings.
• Allogeneic iPS Cell-Derived Corneal Endothelial Cells (他家iPS細胞由来角膜内皮細胞) Regenerative medicine product comprising corneal endothelial cells derived from allogeneic human iPS cells, developed for anterior chamber injection therapy targeting severe bullous keratopathy. Cells are isolated from the second band structure of SEAM to produce functional corneal endothelial cells.

Quantifiable outcome

• All 4 patients in First-in-Human study showed improvement in limbal stem cell deficiency and corrected visual acuity with decreased corneal opacity, and zero tumor formation or rejection
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor and core.

• P.S. i LOVE YOU PROJECTminorGTM or Marketing Partner · 14 February 2022RAYMEI participates in the P.S. i LOVE YOU PROJECT together with CiRA_F and other companies using iPS cell stocks. This initiative aims to promote awareness and understanding of iPS cell-based regenerative medicine among the general public, launched on Valentine's Day. Companies in this coalition share thoughts on iPS cell-based regenerative medicine commercialization.
• Kyoto University iPS Cell Research Foundation (CiRA_F)coreStrategic or Co-development Partner · 5 March 2019CiRA_F provides allogeneic iPS cells for RAYMEI's clinical research and product development. The company sources HLA homozygous iPS cells from CiRA_F for manufacturing corneal epithelial cell sheets. This partnership is critical for raw material supply for the regenerative medicine products.
• Osaka University (Department of Ophthalmology)coreStrategic or Co-development Partner · 1 January 2016RAYMEI was established in 2016 to commercialize the SEAM technology developed by Professor Koji Nishida's group at Osaka University's Department of Ophthalmology. The company maintains a close R&D partnership with the university, with the company's R&D office located in Osaka University's Industry-University Co-creation Building. Professor Nishida serves as Scientific Technical Advisor.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RAYMEI